Oncology Clinical Trial Finder
Breast Cancer

Recruiting • Phase NA • Stage IV • ER positive • Post-Menopausal • Interventional

The following is imported from ClinicalTrials.gov:

[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial

This protocol is a companion imaging study that will add FES-PET/CT imaging to the FORESEE trial at HCI. This study will establish the feasibility of using FES-PET/CT imaging to guide therapeutic decision making for functional precision oncology trials. The unique ability of FES-PET/CT to show absence of functional estrogen receptors throughout the entire body may improve confidence among research oncologists that an ER+ metastatic breast cancer patient is truly refractory to hormonal therapies which is a critical determination in the study design of the FORESEE trial.

Breast Cancer

Study Design
Study type:


Estimated enrollment:

6 participant

Actual study start date:

March 31, 2021

Eligibility Criteria
Ages eligible for study:

18 - 999

Sexes eligible for study:


Arms and Intervention
  • [18F]Fluoroestradiol (FES) PET/CT

Inclusion criteria
  • adults aged 18 years or greater.

  • all patients or legal guardians are willing and able to sign written informed consent and hipaa authorization in accordance with local and institutional guidelines.

  • enrolled on the foresee trial.

  • biopsy proven estrogen receptor positive breast cancer.

  • patient deemed refractory to all combinations of hormonal therapies by foresee trial investigators.

Exclusion criteria
  • patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals. patients with significant drug or other allergies or autoimmune diseases may be enrolled at the investigator's discretion.

  • patients who require monitored anesthesia for pet/ct scanning.

  • patients who are too claustrophobic to undergo pet/ct scanning.

  • patients who are pregnant or currently breast feeding.

  • any patient that is medically unstable defined as a patient requiring inpatient hospitalization or needing evaluation at an acute care or urgent care facility at the time of imaging.

Trial Information at Site
Last Updated:
Trial Information
ClinicalTrial.gov ID:


Estimated Enrollment:


Last Updated:


Site Contact

Matt Covington, MD



Huntsman Cancer Institute at University of Utah

Salt Lake City, Utah, United States, 84112

Trial Contact

Paige Nielsen



Matthew Covington, MD



Principal Investigator

Matthew Covington, MD

Trial Sponsor

University of Utah

Study Location (1)

Huntsman Cancer Institute at University of Utah

Salt Lake City, Utah, United States


© 2024 Outcomes4Me Inc. All rights reserved.